Congratulations to CG Oncology, Inc. on the impressive results from their Phase 3 BOND-003 trial of cretostimogene. A 75.2% complete response rate in BCG-unresponsive NMIBC is a significant step forward for bladder cancer treatment.

This progress in #oncolytic #immunotherapy aligns…

Latest Equity Research from Roth Capital Partners
Price Target of A$0.42
IMU: General Quarterly Business Update, 2H24 To Be Rich In Clinical Data

Read the full $IMU Report here: tinyurl.com/35vf9r4x

#equityresearch #equityrelease #CancerResearch #CancerTherapy #ASX IMU #ASX …

Today, our CEO and Managing Director, Leslie Chong, had the pleasure of presenting at the JustStocks event in #Melbourne during an #investor luncheon. Leslie provided a comprehensive update on our company’s progress and future plans.
$IMU JustStocks_au

We're pleased to present our Activities Report for the period to 31 March 2024.

View our complete Quarterly Report here: ⬇️
app.sharelinktechnologies.com/announcement/a…

$IMU #ASX #ASX News #CancerResearch #Immunotherapy #ClinicalResearch #CancerTreatment #Immunooncology

Cholangiocarcinoma Annual Conference Poster Presentation: 'CF33-hlMIS, a Novel Oncolytic Virus for the Treatment of #Cholangiocarcinoma and Biliary Tract Malignancies.'

Presented by:
Dr Paul Woodard Ph.D. Imugene

#CancerResearch #Immunotherapy $IMU #biotech

Dr. Bilal Shah, Associate Member in the Department of Malignant Hematology at the Moffitt Cancer Center, delivered an encore presentation featuring previously presented azer-cel data at the iwCAR-T 2024 meeting on April 19 in Miami, Florida. iwCAR-T is an annual workshop led by…

Diamond Equity Research: Price Target of A$0.49
IMU: Strategic Sale of North Carolina Facility and Clinical Trial Expansions Advancing

View the $IMU full Report here: tinyurl.com/467kh9du

Latest Equity Research from Senior Analyst John Hester at Bell Potter Securities: Price Target of A$0.15
IMU: Core Assets Progressing Nicely

Read the full Report here: tinyurl.com/4e28zfcu

$IMU #equityresearch #equityrelease #CancerResearch #CancerTherapy #ASX IMU #ASX …

We're thrilled to share the recording of our recent investor webinar discussing the strategic partnership between Imugene Limited and Kincell Bio.

Watch here: youtu.be/t5eI6-s2Y4s?si…

Join MD & CEO Leslie Chong, COO Dr. Bradley Glover, and Kincell Bio's CEO, Dr. Bruce Thompson…

We're honoured to have presented our innovative CF33-hNIS (VAXINIA) technology at the prestigious Cholangiocarcinoma Foundation Annual Conference. It was a remarkable opportunity to share our research and insights on a novel oncolytic virus for the treatment of cholangiocarcinoma…

In a recent discussion with JustStocks_au, our MD and CEO Leslie Chong talked about significant developments at Imugene, including the expansion of our clinical study for Bile Tract #Cancer patients and a strategic new partnership with Kincell Bio.

Leslie will be presenting at…

Latest Equity Research from Roth Capital Partners: Price Target of A$0.42

IMU: Sells CGMP Facility That Manufactures Azer-cel, MAST Trial Making Progress

Full $IMU Research Report here: tinyurl.com/dxecf6sv

#equityresearch #equityrelease #CancerResearch #CancerTherapy …

We are excited to share our recent feature on ausbiz where Managing Director and CEO, Leslie Chong, discusses our new strategic partnership with Kincell Bio. This collaboration represents a significant advancement in our commitment to revolutionise #cancer treatment through…

Join our Managing Director and CEO, Leslie Chong, as she sits down with Proactive Australia's Jonathan Jackson to discuss our new partnership with Kincell Bio. Discover how this strategic move involving the sale of our CGMP-compliant cell therapy manufacturing facility in North…

We will hold an investor webinar on Thursday, 18 April 2024, at 10am AEST to discuss the strategic partnership announced with Kincell Bio.

Presenting as part of the webinar will be our MD and CEO Leslie Chong, COO Dr Bradley Glover and Kincell Bio's CEO Dr Bruce Thompson. It…

🗞️Imugene and Kincell Bio form manufacturing and process development partnership | $IMU Media coverage by Proactive Australia.

proactiveinvestors.com.au/companies/news…

We are pleased to announce a strategic partnership with Kincell Bio to support the development and manufacturing of our lead product candidate, Azer-cel.

MD and CEO Leslie Chong commented, “We are delighted to have found a strong partner for the development and manufacturing of…

'As a team, we’re particularly eager to begin the #cholangiocarcinoma expansion study, given the meaningful difference we’ve seen #VAXINIA make for patients with #gastrointestinal #cancers , Managing Director and CEO Leslie Chong said.

🗞️ $IMU Media covered by The West Australian…

🗞️Imugene expands bile tract #cancer study as patient shows complete response during MAST trial phase | Media coverage by Proactive Australia.

proactiveinvestors.com.au/companies/news… $IMU #ASXnews